Eisai sales and marketing update

Eisai established a patient access program to ensure availability of epilepsy drug Fycompa perampanel in Germany. The program will be managed by Clinigen Global Access Programs (Clinigen GAP), part of Clinigen Group plc (LSE:CLIN, Burton-on-Trent, U.K.). Eisai said it does not expect the program to be used until early 2014, as stocks of Fycompa in Germany should meet demand until year end. ...